The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial

Shohan, Mojtaba; Nashibi, Roohangiz; Mahmoudian-Sani, Mohammad-Reza; Abolnezhadian, Farhad; Ghafourian, Mehri; Alavi, Seyed Mohammad; Sharhani, Asaad; Khodadadi, Ali

doi:10.1016/j.ejphar.2021.174615

Cited by 74 publications

(93 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another inhibitor of the NLRP3 inflammasome, low-dose melatonin was investigated by some clinical trials as a potential treatment for COVID-19 (NCT04409522), leading to improvements in the clinical condition and plain radiographs of the patients ( 22 ). Recently, in another study, we showed that quercetin (NLRP3 inhibitor) is effective in lowering the serum levels of q-CRP, and LDH as critical markers involved in COVID-19 severity ( 23 ). Other NLRP3 inflammasome inhibitors and immunomodulators investigated in the clinical trials as potential COVID-19 treatments include statins, sirolimus, azithromycin, cyclosporine, oridonin, quercetin, and curcumin ( 24 , 25 ), as well as Tranilast, which was evaluated in the present study.…”

Section: Discussionmentioning

confidence: 99%

Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial

Saeedi-Boroujeni

Nashibi

Ghadiri

et al. 2022

Archives of Medical Research

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial

Saeedi-Boroujeni

Nashibi

Ghadiri

et al. 2022

Archives of Medical Research

Self Cite

View full text Add to dashboard Cite

“…Besides, earlier discharge time was observed in the patients who were taking quercetin. In general, those patients showed better clinical improvements in terms of the COVID-19 symptoms ( 87 ).…”

Section: Effect Of Phenolic Compounds On Specific Pathologiesmentioning

confidence: 99%

Red Wine and Health: Approaches to Improve the Phenolic Content During Winemaking

Vejarano

Luján-Corro

2022

Front. Nutr.

View full text Add to dashboard Cite

There is ample evidence regarding the health benefits of red wine consumption due to its content of phenolic compounds, as an alternative to improve the state of health and prevent various diseases, being the implementation of procedures that allow a greater extraction and stability of phenolic compounds during the elaboration a key aspect. The first part of this review summarizes some studies, mostly at the preclinical level, on the mechanisms by which phenolic compounds act in the human organism, taking advantage of their antioxidant, anti-inflammatory, antitumor, antithrombotic, antiatherogenic, antimicrobial, antiviral, and other activities. Although the migration of grape components into the must/wine occurs during the winemaking process, the application of new technologies may contribute to increasing the content of phenolic compounds in the finished wine. Some of these technologies have been evaluated on an industrial scale, and in some cases, they have been included in the International Code of Oenological Practice by the International Organization of Vine and Wine (OIV). In this sense, the second part of this review deals with the use of these novel technologies that can increase, or at least maintain, the polyphenol content. For example, in the pre-fermentative stage, phenolic extraction can be increased by treating the berries or must with high pressures, pulsed electric fields (PEF), ultrasound (US), e-beam radiation or ozone. At fermentative level, yeasts with high production of pyranoanthocyanins and/or their precursor molecules, low polyphenol absorption, and low anthocyanin-β-glucosidase activity can be used. Whereas, at the post-fermentative level, aging-on-lees (AOL) can contribute to maintaining polyphenol levels, and therefore transmitting health benefits to the consumer.

show abstract

“…In summary, accumulating evidence deriving from both computational and experimental studies suggests that quercetin, as other phenolic compounds, can act at multiple levels to inhibit or reduce the infectivity of coronaviruses including SARS‐CoV and SARS‐CoV‐2 although only very recently the clinical efficacy of these treatments have been explored (Bernini & Velotti, 2021 ; Di Pierro, Derosa, et al, 2021 ; Di Pierro, Iqtadar, et al, 2021 ; Rondanelli et al, 2022 ; Shohan et al, 2022 ).…”

Section: Anti‐ Severe Acute Respiratory Syndrome Coronavirus‐2 ( ...mentioning

confidence: 99%

“…In the “quercetin group,” the protection to contract the COVID‐19 infection was 14% compared to the “placebo group” and the complete clinical remission was shorter (7 vs. 15 days) in the former with respect to the latter (Rondanelli et al, 2022 ). Finally, in a different study, COVID‐19 patients receiving for 7 days 1 g of quercetin plus conventional antiviral drugs (remdesivir or favipiravir) showed reduced levels of critical markers involved in COVID‐19 severity (e.g., ALP, q‐CRP, and LDH) (Shohan et al, 2022 ).…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

A critical evaluation of risk to reward ratio of quercetin supplementation for COVID‐19 and associated comorbid conditions

Pawar

Russo

Rani

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

The interim results of the large, multinational trials on coronavirus disease 2019 (COVID‐19) using a combination of antiviral drugs appear to have little to no effect on the 28‐day mortality or the in‐hospital course. Therefore, there is a still vivid interest in finding alternate re‐purposed drugs and nutrition supplements, which can halt or slow the disease severity. We review here the multiple preclinical studies, partially supported by clinical evidence showing the quercetin's possible therapeutic/prophylaxis efficacy against severe acute respiratory syndrome coronavirus (SARS‐CoV) as well as comorbidities like chronic obstructive pulmonary disease (COPD), diabetes mellitus, obesity, coagulopathy, and hypertension. Currently, 14 interventional clinical trials are underway assessing the efficacy of quercetin along with other antiviral drugs/nutritional supplements as prophylaxis/treatment option against COVID‐19. The present review is tempting to suggest that, based on circumstantial scientific evidence and preliminary clinical data, the flavonoid quercetin can ameliorate COVID‐19 infection and symptoms acting in concert on two parallel and independent paths: inhibiting key factors responsible for SARS‐CoV‐2 infections and mitigating the clinical manifestations of the disease in patients with comorbid conditions. Despite the broad therapeutic properties of quercetin, further high power randomized clinical trials are needed to firmly establish its clinical efficacy against COVID‐19.

show abstract

The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial

Cited by 74 publications

References 36 publications

Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial

Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial

Red Wine and Health: Approaches to Improve the Phenolic Content During Winemaking

A critical evaluation of risk to reward ratio of quercetin supplementation for COVID‐19 and associated comorbid conditions

Contact Info

Product

Resources

About